NEW YORK, May 16, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for Alzheimer's disease and other serious neurodegenerative conditions, with an internal diversified pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today it has appointed Dr. Michael Grundman MD, MPH, to its Clinical Advisory Board. Dr. Grundman is President and CEO at Global R&D Partners, LLC, a consulting firm that works closely with pharmaceutical and biotechnology companies to develop novel agents for the diagnosis and treatment of serious and life threatening diseases. Dr. Grundman currently is an Adjunct Professor of Neurosciences at the University of California San Diego (UCSD). Previously he served as Vice President of Clinical Development at Janssen Alzheimer Immunotherapy Research & Development, LLC and as Vice President of Clinical Development at Elan Pharmaceuticals.
